BioCentury | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

...duration of HBsAg reduction through day 85. Christine Esau, director of translational biology at the RNA medicines...
BioCentury | Oct 6, 2017
Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...
BioCentury | Jul 28, 2014
Company News

Beth Israel Deaconess cancer, gene/cell therapy news

Beth Israel’s cancer center launched the Institute for RNA Medicine to identify non-coding RNA pathways and develop therapeutics targeting the pathways. The institute will use the cancer center’s “mouse hospital” in which mice are genetically...
Items per page:
1 - 3 of 3
BioCentury | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

...duration of HBsAg reduction through day 85. Christine Esau, director of translational biology at the RNA medicines...
BioCentury | Oct 6, 2017
Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...
BioCentury | Jul 28, 2014
Company News

Beth Israel Deaconess cancer, gene/cell therapy news

Beth Israel’s cancer center launched the Institute for RNA Medicine to identify non-coding RNA pathways and develop therapeutics targeting the pathways. The institute will use the cancer center’s “mouse hospital” in which mice are genetically...
Items per page:
1 - 3 of 3